Ankit Sharma1,2, Anne Taverniti3, Nicole Graf4, Armando Teixeira-Pinto3,5, Joshua R Lewis3,6,7, Wai H Lim7,8, Stephen I Alexander3, Anne Durkan3, Jonathan C Craig3,5,9, Germaine Wong3,5. 1. Centre for Kidney Research, Children's Hospital at Westmead, Sydney, Australia. ankit.sharma@health.nsw.gov.au. 2. School of Public Health, Sydney Medical School, The University of Sydney, Sydney, Australia. ankit.sharma@health.nsw.gov.au. 3. Centre for Kidney Research, Children's Hospital at Westmead, Sydney, Australia. 4. Department of Histopathology, Children's Hospital at Westmead, Sydney, Australia. 5. School of Public Health, Sydney Medical School, The University of Sydney, Sydney, Australia. 6. School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia. 7. School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. 8. Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia. 9. College of Medicine and Public Health, Flinders University, Adelaide, Australia.
Abstract
BACKGROUND: The longitudinal relationship between HLA class I and II eplet mismatches, de novo donor-specific antibodies (dnDSA) development, and acute rejection after transplantation in childhood is unknown. METHODS: Eplet mismatches at HLA class I and II loci were calculated retrospectively for each donor/recipient pair transplanted between 2005 and 2015 at a single Australian center. Logistic regression analyses were conducted to determine the association between the number of eplet mismatches, dnDSA, and acute rejection. RESULTS: The cohort comprised 59 children (aged 0-18 years) who received their first kidney allograft and were followed for median (interquartile range) 4.5 (± 2.6) years. Overall, 32% (19/59) developed dnDSA (class I 3% (2/59), class II 14% (8/59), 15% class I and II (9/59)), and 24% (14/59) developed biopsy-proven acute rejection. Every unit increase in class I and II eplet mismatches corresponded to an increase in risk of class I (odds ratio (OR) 1.22, 95% CI 1.07-1.39, p < 0.01) and class II (OR 1.06, 95% CI 1.01-1.11, p = 0.02) dnDSA development. Compared with recipients without dnDSA, class I and II dnDSA were associated with direction of effect towards increased risk of acute cellular rejection (class I: OR 5.87, 95% CI 0.99-34.94, p = 0.05; class II: OR 12.00, 95% CI 1.25-115.36, p = 0.03) and acute antibody-mediated rejection (class I: OR 25.67, 95% CI 3.54-186.10, p < 0.01; class II: OR 9.71, 95% CI 1.64-57.72, p = 0.01). CONCLUSIONS: Increasing numbers of HLA class I or II eplet mismatches were associated with the development of dnDSA. Children who developed dnDSA were also more likely to develop acute rejection compared with children without dnDSA.
BACKGROUND: The longitudinal relationship between HLA class I and II eplet mismatches, de novo donor-specific antibodies (dnDSA) development, and acute rejection after transplantation in childhood is unknown. METHODS: Eplet mismatches at HLA class I and II loci were calculated retrospectively for each donor/recipient pair transplanted between 2005 and 2015 at a single Australian center. Logistic regression analyses were conducted to determine the association between the number of eplet mismatches, dnDSA, and acute rejection. RESULTS: The cohort comprised 59 children (aged 0-18 years) who received their first kidney allograft and were followed for median (interquartile range) 4.5 (± 2.6) years. Overall, 32% (19/59) developed dnDSA (class I 3% (2/59), class II 14% (8/59), 15% class I and II (9/59)), and 24% (14/59) developed biopsy-proven acute rejection. Every unit increase in class I and II eplet mismatches corresponded to an increase in risk of class I (odds ratio (OR) 1.22, 95% CI 1.07-1.39, p < 0.01) and class II (OR 1.06, 95% CI 1.01-1.11, p = 0.02) dnDSA development. Compared with recipients without dnDSA, class I and II dnDSA were associated with direction of effect towards increased risk of acute cellular rejection (class I: OR 5.87, 95% CI 0.99-34.94, p = 0.05; class II: OR 12.00, 95% CI 1.25-115.36, p = 0.03) and acute antibody-mediated rejection (class I: OR 25.67, 95% CI 3.54-186.10, p < 0.01; class II: OR 9.71, 95% CI 1.64-57.72, p = 0.01). CONCLUSIONS: Increasing numbers of HLA class I or II eplet mismatches were associated with the development of dnDSA. Children who developed dnDSA were also more likely to develop acute rejection compared with children without dnDSA.
Authors: Robert C Williams; Gerhard Opelz; Chelsea J McGarvey; E Jennifer Weil; Harini A Chakkera Journal: Transplantation Date: 2016-05 Impact factor: 4.939
Authors: Kyle J Van Arendonk; Jacqueline M Garonzik Wang; Neha A Deshpande; Nathan T James; Jodi M Smith; Robert A Montgomery; Paul M Colombani; Dorry L Segev Journal: Transplantation Date: 2013-06-15 Impact factor: 4.939
Authors: Marlies K A Dankers; Marian D Witvliet; Dave L Roelen; Peter de Lange; Nelleke Korfage; Guido G Persijn; René Duquesnoy; Ilias I N Doxiadis; Frans H J Claas Journal: Transplantation Date: 2004-04-27 Impact factor: 4.939
Authors: C Wiebe; D Pochinco; T D Blydt-Hansen; J Ho; P E Birk; M Karpinski; A Goldberg; L J Storsley; I W Gibson; D N Rush; P W Nickerson Journal: Am J Transplant Date: 2013-10-25 Impact factor: 8.086
Authors: Vasilios Kosmoliaptsis; Olivera Gjorgjimajkoska; Linda D Sharples; Afzal N Chaudhry; Nikolaos Chatzizacharias; Sarah Peacock; Nicholas Torpey; Eleanor M Bolton; Craig J Taylor; J Andrew Bradley Journal: Kidney Int Date: 2014-04-09 Impact factor: 10.612
Authors: M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel Journal: Am J Transplant Date: 2018-01-21 Impact factor: 8.086
Authors: Steven J Hiho; Duncan C Walton; Miranda A Paraskeva; Bronwyn J Levvey; Mary B Diviney; Gregory I Snell; Lucy C Sullivan; Glen P Westall Journal: Transplant Direct Date: 2022-09-16
Authors: Olga Charnaya; June Jones; Mary Carmelle Philogene; Po-Yu Chiang; Dorry L Segev; Allan B Massie; Jacqueline Garonzik-Wang Journal: Pediatr Nephrol Date: 2021-06-07 Impact factor: 3.651